113 related articles for article (PubMed ID: 3134000)
21. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
Masson C; Angles-Cano E
Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
[TBL] [Abstract][Full Text] [Related]
22. Vancomycin levels after intravitreal injection. Effects of inflammation and surgery.
Aguilar HE; Meredith TA; el-Massry A; Shaarawy A; Kincaid M; Dick J; Ritchie DJ; Reichley RM; Neisman MK
Retina; 1995; 15(5):428-32. PubMed ID: 8594637
[TBL] [Abstract][Full Text] [Related]
23. Enzyme linked fibrinolytic assay (ELFA). A new method for the measurement of t-PA in plasma using enzyme labelled fibrin.
Triscott MX; Bottoms JD; Beard GA; Doellgast GJ
Thromb Res; 1990 Aug; 59(4):723-33. PubMed ID: 2127866
[TBL] [Abstract][Full Text] [Related]
24. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
25. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Wu WC; Chang SM; Chen JY; Chang CW
J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
27. [The correlation study of the expression of VEGF with t-PA and PAI expression in plasma and intraocular tissue in proliferative diabetic retinopathy].
Wu S; He X
Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):448-53. PubMed ID: 25241978
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.
Colucci M; Paramo JA; Collen D
J Lab Clin Med; 1986 Jul; 108(1):53-9. PubMed ID: 3086473
[TBL] [Abstract][Full Text] [Related]
29. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
Paoni NF; Keyt BA; Refino CJ; Chow AM; Nguyen HV; Berleau LT; Badillo J; Peña LC; Brady K; Wurm FM
Thromb Haemost; 1993 Aug; 70(2):307-12. PubMed ID: 8236140
[TBL] [Abstract][Full Text] [Related]
30. In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.
Tsukamoto E
Ann Nucl Med; 1992 Aug; 6(3):177-84. PubMed ID: 1389893
[TBL] [Abstract][Full Text] [Related]
31. Clearance of intravitreal moxifloxacin.
Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):317-9. PubMed ID: 16384979
[TBL] [Abstract][Full Text] [Related]
32. Clearance and distribution of ciprofloxacin after intravitreal injection.
Pearson PA; Hainsworth DP; Ashton P
Retina; 1993; 13(4):326-30. PubMed ID: 8115734
[TBL] [Abstract][Full Text] [Related]
33. In vivo kinetics of 99mTc labeled recombinant tissue plasminogen activator in rabbits.
Itoh K; Ieko M; Hiraguchi E; Kitayama H; Tsukamoto E
Ann Nucl Med; 1994 Aug; 8(3):193-9. PubMed ID: 7811562
[TBL] [Abstract][Full Text] [Related]
34. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
35. [Plasminogen activator and PAI. Detection in aqueous humor of the human eye].
Steinkamp GW; Hattenbach LO; Heider HW; Scharrer I
Ophthalmologe; 1993 Feb; 90(1):73-5. PubMed ID: 8443455
[TBL] [Abstract][Full Text] [Related]
36. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
[TBL] [Abstract][Full Text] [Related]
37. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
38. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.
Wing LR; Hawksworth GM; Bennett B; Booth NA
J Lab Clin Med; 1991 Feb; 117(2):109-14. PubMed ID: 1899689
[TBL] [Abstract][Full Text] [Related]
39. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
40. Intraocular kinetics of ceftazidime (Modacin).
Mochizuki K; Yamashita Y; Torisaki M; Komatsu M; Tanahashi T; Kawasaki K
Ophthalmic Res; 1992; 24(3):150-4. PubMed ID: 1407956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
